Vyvanse capsules Product Alert: 20 mg to 70 mg
03 Apr 2025
Takeda Pharmaceuticals Australia Pty Ltd has issued a Product Alert for Vyvanse capsules in the following strengths: 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. See the table below for details of affected batches.
What is the problem?
Takeda has found two small printing errors on the current Vyvanse packaging:
-
The label says “Each capsules contain…” instead of the correct “Each capsule contains…”.
-
The company name is misspelled as “Pharmaceutivals” instead of “Pharmaceuticals”.
These mistakes have led to customer complaints, social media concerns, and more reports of suspected side effects.
What are the risks?
These packaging errors do not affect the quality or safety of Vyvanse capsules.
What should patients do?
-
Continue taking Vyvanse as prescribed by your health professional.
-
If you have any concerns about using this medicine, speak with your doctor or pharmacist.
Vyvanse capsules included in this alert
| ARTG number | Strength | Product code | Affected batches | Distributed since | Expiry dates |
|---|---|---|---|---|---|
| 284019 | 20 mg | 6510064 | Various Batches | April 2024 | Sep 2026 – Mar 2028 |
| 1992273 | 30 mg | 6510065 | Various Batches | – | Oct 2026 – Mar 2028 |
| 284020 | 40 mg | 6510063 | Various Batches | – | Oct 2026 – Mar 2028 |
| 1992265 | 50 mg | 6510060 | Various Batches | – | Oct 2026 – Mar 2028 |
| 284021 | 60 mg | 6510062 | Various Batches | – | Oct 2026 – Mar 2028 |
| 1992287 | 70 mg | 6510061 | Various Batches | – | Oct 2026 – Mar 2028 |
Further information
-
After concerns were raised on social media, the TGA received more reports of suspected side effects, including reports that Vyvanse may not be working as well.
-
The TGA is:
-
continuing investigations into these reports,
-
working with Takeda for more information, and
-
carrying out independent testing in its own laboratories.
-
-
If any safety or effectiveness problems are confirmed, the TGA will take regulatory action.
-
Reports of side effects are de-identified and published in the Database of Adverse Event Notifications (DAEN) two weeks after submission.
Reporting problems
-
Patients and health professionals are encouraged to report any problems with medicines or vaccines.
-
These reports help the TGA monitor safety issues.
-
The TGA cannot give individual medical advice — if you are worried about Vyvanse or possible side effects, speak to your doctor or pharmacist.
Source TGA
